Esmo Open

A critical review of key studies from the ASCO 2016 Gastrointestinal Cancers Symposium, held January 2016, is presented in this podcast. A number of tumor areas, including gastric, esophageal and colorectal cancers, are considered with an emphasis on recent developments in immunotherapy. Studies reviewed include the CheckMate-032 trial, which assessed the activity of the anti-PD-1 antibody nivolumab in patients with advanced gastric or gastroesophageal junction cancer, the KEYNOTE-028 trial, for which results of the esophageal carcinoma cohort treated with pembrolizumab were presented, and updated results of a trial considering PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. Biomarkers are further considered in the Mavericc trial which sought to stratify metastatic colorectal cancer patients by ERCC1 in order to predict their response to platinum-based treatments. Neoadjuvant therapy was considered with the results of a study, from the Polish Colorectal Study Group, u